Skip to content

A multicenter, double arm clinical study to assess the safety & efficacy of CardioSAM ECG against the conventional 12 channel ECG

A multi centre double arm clinical study to assess the safety & efficacy of CardioSAM-DRSMARTHEART Simultaneous 12 channel Resting Digital ECG against the conventional 12 channel ECG

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/032160
Enrollment
180
Registered
2021-03-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z018- Encounter for other specified special examinations

Interventions

Intervention1: CardioSAM-DRSMARTHEART ECG MACHINE: Standard Simultaneous 12 channel Resting Digital ECG is used to take ECG on same day. Control Intervention1: 12 Channel ECG: GE MAC 1200 ST

Sponsors

Samtech Devices India Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects of age between 18 to 60. 2.For whom the Investigator considers that the compliance will be correct. 3.Cooperating, informed of the need and duration of the study, and ready to comply with protocol procedures. 4.Having signed a Consent Form and will be once informed orally and in writing of all information concerning the study procedures and study objectives.

Exclusion criteria

Exclusion criteria: 1.Volunteers with any cardiac abnormalities or ailments or abnormal blood pressure. 2.Known sensitivity to the investigational product

Design outcomes

Primary

MeasureTime frame
The primary endpoint of the study would be the efficacy of the IP which will be assessed by assessing the ECG results from Investigational Product and comparative productTimepoint: The primary endpoint of the study would be the efficacy of the IP which will be assessed by assessing the ECG results from Investigational Product and comparative product on vist 2

Secondary

MeasureTime frame
The Secondary end-points of this study would be safety and adverse eventsTimepoint: Visit 2

Countries

India

Contacts

Public ContactSuresh Jeevarathinam

Innovitae Clinical Research Services Pvt Ltd

prathap.vc@innovitae.in9400144281

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026